Early Access — free while we kick the tires
EdgarHawk

ABERNETHY MATT

Chief Financial Officer

Officer
1 filing analyzed · 1 company · Latest 2024-08-15

Companies

Company Buys Sells Direction
NEUROCRINE BIOSCIENCES INC NBIX 0 2 Net selling

Activity

August 2024
medium
Sell
14,100 shares
$2,120,347
Significance 5/10

CFO Abernethy sold 14,100 shares of NBIX at $150.38 for $2.1M; holdings reduced 30.9% to 31.5K shares

CFO Matt Abernethy sold 14,100 shares at $150.38 on 2024-08-13, reducing his position by 30.9% to 31,528 shares remaining. The sale occurred near the 52-week high of $153.15 (-3.5% from peak), with current price at $147.77. Abernethy's prior two sales at NBIX (2024-05-14 and 2024-05-15) were both followed by positive 90-day returns (+0.4% and +7.5% respectively), indicating a pattern of selling before subsequent gains—contrary to well-timed execution on this ticker. His cross-ticker history shows only 2 prior sells with a 0.00% well-timed rate at the 90-day mark. The sale occurs within a company posting strong fundamentals: $590.2M in latest quarterly revenue, +26.8% annual growth, and $65.0M net income, though the P/E of 43.98 reflects elevated valuation expectations.

Related insiders

Create a free account

Build watchlists, get email alerts on the tickers you follow, and read the full AI analysis on every insider filing.

Sign up — free during early access